v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the condensed consolidated statements of earnings for the periods ended March 31, 2025 and 2024. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.
The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)20252024
Immunology
SkyriziUnited States$2,919 $1,656 
International506 352 
Total$3,425 $2,008 
RinvoqUnited States$1,220 $725 
International498 368 
Total$1,718 $1,093 
HumiraUnited States$744 $1,771 
International377 499 
Total$1,121 $2,270 
Neuroscience
VraylarUnited States$763 $692 
International2 2 
Total$765 $694 
Botox TherapeuticUnited States$723 $611 
International143 137 
Total$866 $748 
UbrelvyUnited States$233 $197 
International7 6 
Total$240 $203 
QuliptaUnited States$172 $128 
International21 3 
Total$193 $131 
VyalevUnited States$6 $— 
International57 9 
Total$63 $9 
DuodopaUnited States$20 $25 
International76 90 
Total$96 $115 
Other NeuroscienceUnited States$55 $61 
International4 4 
Total$59 $65 
Three months ended
March 31,
(in millions)20252024
Oncology
ImbruvicaUnited States$529 $610 
Collaboration revenues209 228 
Total$738 $838 
VenclextaUnited States$312 $281 
International353 333 
Total$665 $614 
Elahere
United States
$165 $64 
International
14 — 
Total$179 $64 
Epkinly
Collaboration revenues
$36 $22 
International15 5 
Total$51 $27 
Aesthetics
Botox CosmeticUnited States$295 $389 
International261 244 
Total$556 $633 
Juvederm CollectionUnited States$75 $106 
International156 191 
Total$231 $297 
Other AestheticsUnited States$270 $281 
International45 38 
Total$315 $319 
Eye Care
OzurdexUnited States$30 $34 
International93 97 
Total$123 $131 
Lumigan/GanfortUnited States$48 $29 
International58 62 
Total$106 $91 
Alphagan/CombiganUnited States$26 $15 
International34 44 
Total$60 $59 
Other Eye CareUnited States$117 $149 
International100 108 
Total$217 $257 
Other Key Products
MavyretUnited States$142 $144 
International164 205 
Total$306 $349 
CreonUnited States$355 $285 
Linzess/ConstellaUnited States$139 $257 
International9 9 
Total$148 $266 
All other$747 $744 
Total net revenues$13,343 $12,310 
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7).